跳至主要内容
临床试验/NCT05833282
NCT05833282招募中不适用

Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

Tourcoing Hospital1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2022年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
1
主要终点
The primary endpoint is all-cause 30-day mortality.

研究概览

简要总结

Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

详细描述

INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

PRIMARY ENDPOINT

  • The primary endpoint is 30-day mortality.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

排除标准

  • Patient who is a minor, protected adult, or who refuses to participate.

结局指标

主要结局

The primary endpoint is all-cause 30-day mortality.

时间窗: 30-day mortality

all-cause mortality.

次要结局

  • Adequacy of initial antibiotic therapy to french recommendations(adequate within 30 days)

研究者

发起方
Tourcoing Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验